To further explore the underlying mechanisms, we evaluated treatment effects on tumor-infiltrating lymphocytes (TILs), including CD4-CD8+ T cells, CD4+CD8- T cells, CD4-CD8+GZMB+ T cells (activated CD8+ T cells) and CD4+CD8-CD25+FXOP3+ (Tregs) (Figure 8F). The gene discussed is CD4; the disease is neoplasm.